Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics.
Sector: Life Sciences
Caribou Biosciences
Caribou (NASDAQ: CRBU) is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies.
Semma Therapeutics
Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. This company was acquired by Vertex in 2019.
Avidity Biosciences
Avidity Biosciences is a biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease. Avidity Biosciences, (formerly NASDAQ: RNA/RNAM) is no longer a publicly traded company. Novartis acquired Avidity.
Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface Oncology went public in 2018 (NASDAQ: SURF). The company has since been acquired by Coherus BioSciences and is no longer a publicly traded company. Surface Oncology was acquired in 2023.
Cogent Biosciences
Cogent Biosciences (NASDAQ:COGT) (formerly Unum Therapeutics) is developing precision therapies for genetically defined diseases with a clinical stage therapy for systemic mastocytosis.
Adaptimmune
Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Adaptimmune was acquired by WorldMeds in 2025.
Kevin Chu
Kevin Chu joined F-Prime in 2014 and is currently a Principal on the healthcare investment team based in San Francisco. Prior to F-Prime, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy.
At F-Prime, Kevin focuses primarily on investments in therapeutics, medical devices, and life science tools companies. He was a member of the founding team at Shinobi Therapeutics, led the fund’s investments in Apreo Health, Amber Therapeutics, Cadence Neuroscience and was involved with several legacy fund investments including Innovent Biologics (1801.HK), Semma Therapeutics (acquired by Vertex), Modis Therapeutics (acquired by Zogenix), Farapulse (acquired by Boston Scientific), Cytek Biosciences (NASDAQ: CTKB), and Sipai Health Technology (0314.HK). He also works closely with the Eight Roads Ventures China team to manage F-Prime’s healthcare investment efforts in China.
Kevin holds a B.S.E. from the University of Pennsylvania where he studied Bioengineering and Engineering Entrepreneurship.
ViewRay
ViewRay (NASDAQ: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. Which uses a high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology.
Trivitron Healthcare
Trivitron Healthcare is India’s largest, national wholesale distributor and after-sales support provider of medical equipment and devices.